Unknown

Dataset Information

0

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.


ABSTRACT: Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid polyneuropathy (ATTR-FAP), is a rare, relentless, fatal hereditary disorder. Tafamidis, an oral, non-NSAID, highly specific transthyretin stabilizer, demonstrated safety and efficacy in slowing neuropathy progression in early-stage ATTRV30M-FAP in a 1.5-year, randomized, double-blind, placebo-controlled trial, and 1-year open-label extension study, with a second long-term open-label extension study ongoing. Subgroup analysis of the effectiveness of tafamidis in the pivotal study and its open-label extensions revealed a relatively cohesive cohort of patients with mild neuropathy (i.e. Neuropathy Impairment Score for Lower Limbs [NIS-LL] ≤ 10) at the start of active treatment. Early treatment with tafamidis for up to 5.5 years (≥1 dose of tafamidis meglumine 20 mg once daily during the original trial or after switching from placebo in its extension) resulted in sustained delay in neurologic progression and long-term preservation of nutritional status in this cohort. Mean (95% CI) changes from baseline in NIS-LL and mBMI were 5.3 (1.6, 9.1) points and -7.8 (-44.3, 28.8) kg/m2 × g/L at 5.5 years, respectively. No new safety issues or side effects were identified. These data represent the longest prospective evaluation of tafamidis to date, confirm a favorable safety profile, and underscore the long-term benefits of early intervention with tafamidis.

Trial registration

ClincalTrials.gov Identifier: NCT00409175, NCT00791492, and NCT00925002.

SUBMITTER: Waddington Cruz M 

PROVIDER: S-EPMC5359776 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.

Waddington Cruz Márcia M   Amass Leslie L   Keohane Denis D   Schwartz Jeffrey J   Li Huihua H   Gundapaneni Balarama B  

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20160805 3


Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid polyneuropathy (ATTR-FAP), is a rare, relentless, fatal hereditary disorder. Tafamidis, an oral, non-NSAID, highly specific transthyretin stabilizer, demonstrated safety and efficacy in slowing neuropathy progression in early-stage ATTRV30M-FAP in a 1.5-year, randomized, double-blind, placebo-controlled trial, and 1-year open-label extension study, with a second long-term open-label extens  ...[more]

Similar Datasets

| S-EPMC4098875 | biostudies-literature
| S-EPMC3825212 | biostudies-literature
| S-EPMC6296038 | biostudies-literature
| S-EPMC6325356 | biostudies-literature
| S-EPMC5838526 | biostudies-literature
| S-EPMC4386428 | biostudies-literature
| S-EPMC10495272 | biostudies-literature
| S-EPMC6368811 | biostudies-literature
| S-EPMC6629131 | biostudies-literature
| S-EPMC7156331 | biostudies-literature